Page 84 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $3.15
52wk Low $0.40 GeoVax Labs, Inc. GOVX $0.42
1900 Lake Park Drive
Smyrna, GA 30080

(USD - in millions) www.geovax.com
Market Cap 12.3
Enterprise 7.3
Basic Shares Out. 29.71 COMPANY OVERVIEW
Float 29.61
Institutional Holdings 11.71% Detailed Analysis:Channelchek.com
Short Interest 3.14
Avg. 90-Day Volume 0.80 GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel vaccines against infectious diseases and therapies for
solid tumor cancers. The Company’s lead clinical program is GEO-
CM04S1, a next-generation COVID-19 vaccine currently in three Phase
EPS Data 2 clinical trials, being evaluated as (1) a primary vaccine for
immunocompromised patients such as those suffering from
2022 2023 2024 hematologic cancers and other patient populations for whom the
CQ1 (5.10) (2.25) (2.47) current authorized COVID-19 vaccines are insufficient, (2) a booster
CQ2 (2.70) (3.30) (1.99) vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a
more robust, durable COVID-19 booster among healthy patients who
CQ3 (2.55) (4.80) (0.91) previously received the mRNA vaccines...
CQ4 (3.00) (3.94) (0.30)
CY (12.45) (14.29) (4.82) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.17
ROE (ttm) -377.44
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
S
1900 Lake Par myrna GA 30080

Key Executives
CEO: Dodd, David
CFO: Reynolds, Mark
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures